Filtered By:
Condition: Atrial Fibrillation
Drug: Pradaxa
This page shows you your search results in order of date. This is page number 18.
Order by Relevance | Date
Total 1248 results found since Jan 2013.
Dabigatran for stroke prevention in real life in a sample of population from Turkey: D-SPIRIT registry
CONCLUSION: This registry obtained an important overview of the current safety and effectiveness of the dabigatran etexilate in Turkey. Our results indicate similar rates of thromboembolic and bleeding events with pivotal phase 3 trial and other real-life registries. However, rate of undertreatment usage of dabigatran etexilate in real life was found to be considerable.PMID:34881702 | DOI:10.5543/tkda.2021.07734
Source: Turk Kardiyoloji Dernegi arsivi - December 9, 2021 Category: Cardiology Authors: Cihan Alt ın Caner Topalo ğlu Nurullah Çetin Onur Dalg ıç Veysel Yavuz Emin Alio ğlu Nazile Bilgin Cenk Ekmek çi Nihat Pekel Mehmet Emre Özpelit E şref Tunçer Ebru İpek Türkoğlu Kamil T ülüce Umut Kocaba ş K ıvanç Yüksel U ğur Önsel T Source Type: research
Evaluation of rivaroxaban-, apixaban- and dabigatran-associated hemorrhagic events using the FDA-Adverse event reporting system (FAERS) database
Conclusions Overall, we found a moderate signal of higher frequency of reporting hemorrhage in rivaroxban compared with dabigatran and decreased hemorrhagic event reporting in apixaban compared with dabigatran. While this potential signal has not been confirmed in clinical trials or observational studies, in clinical practice, attention should be paid to the risk of potential hemorrhage when the patients switch from apixaban to dabigatran or rivaroxban.
Source: International Journal of Clinical Pharmacy - December 1, 2021 Category: Drugs & Pharmacology Source Type: research
Efficacy and Safety of Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Liver Disease: a Meta-Analysis and Systematic Review
ConclusionsOur findings suggest that DOACs significantly reduce the risk of ischemic stroke, major bleeding, and ICH, with no significant effect on the risk of gastrointestinal bleeding in AF patients with liver disease compared with warfarin.
Source: Cardiovascular Drugs and Therapy - December 1, 2021 Category: Cardiology Source Type: research
Risk of stroke and other thromboembolic complications after interruption of DOAC therapy compared with warfarin therapy in patients with atrial fibrillation: a retrospective cohort analysis
This study did not find a significant difference in the complication rate after interruption of DOAC therapy compared with interruption of warfarin therapy in hospitalized patients with a high risk of thromboembolism.
Source: Journal of Investigative Medicine - November 25, 2021 Category: Research Authors: Hellerman Itzhaki, M., Greenberg, N., Margalit, I., Shochat, T., Krause, I., Goldberg, E. Tags: Original research Source Type: research
Acute Stroke Treatment in an Anticoagulated Patient: When Is Thrombolysis an Option?
AbstractPurpose of ReviewDirect oral anticoagulants (DOACs: the factor Xa inhibitors rivaroxaban, apixaban, and edoxaban and the direct thrombin inhibitor dabigatran) are the mainstay of stroke prevention in patients with non-valvular atrial fibrillation (AF). Nevertheless, there is a residual stroke risk of 1 –2% per year despite DOAC therapy. Intravenous thrombolysis (IVT) reduces morbidity in patients with ischemic stroke and improves functional outcome. Prior DOAC therapy is a (relative) contraindication for IVT but emerging evidence supports its use in selected patients.Recent FindingsRecent observational studies hi...
Source: Current Treatment Options in Neurology - November 16, 2021 Category: Neurology Source Type: research
Safety and efficacy of low-dose non-vitamin K antagonist oral anticoagulants versus warfarin after left atrial appendage closure with the Watchman device
CONCLUSION: The safety and efficacy of low-dose dabigatran and rivaroxaban were comparable to those of warfarin within 45 days after Watchman device implantation in a Chinese population.PMID:34740490 | DOI:10.1016/j.jfma.2021.10.015
Source: J Formos Med Assoc - November 6, 2021 Category: General Medicine Authors: Guohua Fu Binhao Wang Bin He Yibo Yu Zhao Wang Mingjun Feng Jing Liu Xianfeng Du Weidong Zhuo Huimin Chu Source Type: research
